Diabetes drug competition in focus at ADA meeting - Forbes
With an estimated 19 million Americans suffering from Type 2 diabetes, the market for non-insulin diabetes drugs is worth billions and growing. While Merck & Co.'s Januvia has enjoyed blockbuster success, along with Byetta, made by Amylin and partner
Source: www.forbes.com

UPDATE: Amylin Slides On Byetta Competition Concerns - CNN Money
BOSTON (Dow Jones) -- Amylin Pharmaceuticals' shares skidded for a second day Monday on concerns that its diabetes drug Byetta could soon be facing strong competition from a rival product developed by Danish drugmaker Novo Nordisk A/S . On Friday
Source: money.cnn.com

Amylin falls as Byetta and Exenatide concerns grow - CNN Money
NEW YORK (Associated Press) - Amylin Pharmaceuticals Inc. shares tumbled Monday on threats to the company's diabetes drug Byetta and its longer-lasting drug candidate Exenatide LAR. Byetta is Amylin's top-selling drug, and a long-acting version of
Source: money.cnn.com

Britton boosts gastric band interest - Digital Spy
Enquiries about gastric bands have increased 400% following Fern Britton's confirmation that she underwent the surgery. Consultant surgeon David Hewin said he had received a considerable increase in public interest in the slimming technique since the
Source: www.digitalspy.co.uk

Personal Trainers / Health Care Professionals - Leisure Opportunities
System 10 is an advanced weight loss program that has revolutionised weight loss through Correct Metabolic Repair procedures and Balanced food and exercise plans to suit individual requirements. Currently there are over 30 outlets throughout Ireland
Source: www.leisureopportunities.co.uk

Amylin shares swoon as diabetes rivals emerge - Reuters
NEW YORK (Reuters) - Amylin Pharmaceuticals Inc (AMLN.O: Quote , Profile , Research ) shares fell 10 percent on Monday after data from an important diabetes meeting sparked concern about competition to the company's flagship Byetta medicine. The drop
Source: www.reuters.com

UPDATE 1-Amylin shares swoon as diabetes rivals emerge - Reuters UK
NEW YORK, June 9 (Reuters) - Amylin Pharmaceuticals Inc (AMLN.O: Quote , Profile , Research ) shares fell 10 percent on Monday after data from an important diabetes meeting sparked concern about competition to the company's flagship Byetta medicine
Source: uk.reuters.com

Britton fuels gastric band queries - Croydon Guardian
A leading stomach surgeon has experienced a "400%" increase in inquiries about gastric bands since TV's Fern Britton revealed she lost five stone after the procedure, it has been revealed. David Hewin, consultant surgeon at Gloucestershire Royal
Source: www.croydonguardian.co.uk


HOODIA GORDONII PLUS


PURE HOODIA GORDONII


HOODIA LIQUID